Literature DB >> 18833397

Characterization of virologic failure after an initially successful 48-week course of antiretroviral therapy in HIV/AIDS outpatients treated in Santos, Brazil.

Marcos M Caseiro1, Alcino A C Golegã, Arnaldo Etzel, Ricardo Sobhie Diaz.   

Abstract

We characterized the virologic failure after an initially successful 48-week course of antiretroviral therapy among HIV/AIDS patients in a retrospective cohort study involving patients from Santos, Brazil. Patients with plasma HIV RNA below 500 copies/mL for 48 weeks were included. Variables analyzed included gender, age, level of education, marital status, mode of HIV acquisition, viral load, and CD4 cell count upon admission. There were 4,909 patients registered with the clinic, of which 669 patients met all the inclusion criteria (41.6% female and 58.4% male). Only 27.5% of the patients maintained undetectable viral loads during up to one year of follow-up. After 48 weeks, virologic failure occurred earlier in females and in patients first treated with an antiretroviral regimen other than highly active antiretroviral therapy. Patients who were married or had a steady partner experienced virologic failure later than did those who were separated or widowed. The percentage of public health clinic patients who maintain undetectable viral loads for a period of over a year is much lower than that observed among patients enrolled in clinical trials. Females, individuals in unstable relationships, single individuals and widowed individuals should be given special attention in order to improve durability of viral suppression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18833397     DOI: 10.1590/s1413-86702008000300001

Source DB:  PubMed          Journal:  Braz J Infect Dis        ISSN: 1413-8670            Impact factor:   1.949


  4 in total

1.  Brazilian Network for HIV Drug Resistance Surveillance: a survey of individuals recently diagnosed with HIV.

Authors:  Lilian A Inocencio; Anderson A Pereira; Maria Cecilia A Sucupira; José Carlos C Fernandez; Célia P Jorge; Denise Fc Souza; Helena T Fink; Ricardo S Diaz; Irina M Becker; Theodoro A Suffert; Monica B Arruda; Olinda Macedo; Mariangela Bg Simão; Amilcar Tanuri
Journal:  J Int AIDS Soc       Date:  2009-09-18       Impact factor: 5.396

2.  Use of third line antiretroviral therapy in Latin America.

Authors:  Carina Cesar; Bryan E Shepherd; Cathy A Jenkins; Massimo Ghidinelli; Jose Luis Castro; Valdiléa Gonçalves Veloso; Claudia P Cortes; Denis Padgett; Brenda Crabtree-Ramirez; Eduardo Gotuzzo; Valeria Fink; Adriana Duran; Omar Sued; Catherine C McGowan; Pedro Cahn
Journal:  PLoS One       Date:  2014-09-15       Impact factor: 3.240

3.  Survival benefits of antiretroviral therapy in Brazil: a model-based analysis.

Authors:  Paula M Luz; Michael P Girouard; Beatriz Grinsztejn; Kenneth A Freedberg; Valdilea G Veloso; Elena Losina; Claudio J Struchiner; Rachel L MacLean; Robert A Parker; A David Paltiel; Rochelle P Walensky
Journal:  J Int AIDS Soc       Date:  2016-03-29       Impact factor: 5.396

4.  The Virological and Immunological Characteristics of the HIV-1-Infected Population in Brazil: From Initial Diagnosis to Impact of Antiretroviral Use.

Authors:  Ricardo Sobhie Diaz; Lilian A Inocêncio; Maria Cecilia Araripe Sucupira; Anderson Alvarenga Pereira; James Hunter; João Eduardo Ferreira; Luciano V Araújo; Denise F C Souza; Ester Cerdeira Sabino
Journal:  PLoS One       Date:  2015-10-28       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.